February 1, 2018
Study tracks therapy to slow idiopathic pulmonary fibrosis
Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.
By Nancy Humphrey